Tyme Technologies Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Tyme Technologies stock.
View analyst ratings for Tyme Technologies or view top-rated stocks.

Wall Street analysts have given Tyme Technologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tyme Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Tyme Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, May 19th 2021.
View our earnings forecast for Tyme Technologies.

Tyme Technologies, Inc. (NASDAQ:TYME) released its quarterly earnings data on Thursday, February, 4th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.07) by $0.02.
View Tyme Technologies' earnings history.

Tyme Technologies' stock was trading at $1.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TYME shares have increased by 8.6% and is now trading at $1.14.
View which stocks have been most impacted by COVID-19.

2 analysts have issued 1 year price targets for Tyme Technologies' shares. Their forecasts range from $9.50 to $9.50. On average, they expect Tyme Technologies' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 733.3% from the stock's current price.
View analysts' price targets for Tyme Technologies or view top-rated stocks among Wall Street analysts.

Some companies that are related to Tyme Technologies include Clovis Oncology (CLVS), Evelo Biosciences (EVLO), IVERIC bio (ISEE), Intercept Pharmaceuticals (ICPT), Albireo Pharma (ALBO), Relmada Therapeutics (RLMD), Marinus Pharmaceuticals (MRNS), BELLUS Health (BLUSF), Inventiva (IVA), CytomX Therapeutics (CTMX), Akebia Therapeutics (AKBA), Eagle Pharmaceuticals (EGRX), Magenta Therapeutics (MGTA), Mirum Pharmaceuticals (MIRM) and Veru (VERU).
View all of TYME's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Allena Pharmaceuticals (ALNA), OpGen (OPGN), Selecta Biosciences (SELB), MEI Pharma (MEIP), Pfizer (PFE) and SCYNEXIS (SCYX).

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

Tyme Technologies' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (4.45%), Geode Capital Management LLC (0.98%), Northern Trust Corp (0.62%), HighTower Advisors LLC (0.28%), Barclays PLC (0.07%) and Axiom Investment Management LLC (0.07%). Company insiders that own Tyme Technologies stock include Barbara Galaini, David Carberry, Douglas A Michels, James Biehl, Michael Demurjian, Michele Ilene Korfin, Steve Hoffman and Tornout Jan M Van.
View institutional ownership trends for Tyme Technologies.

TYME stock was sold by a variety of institutional investors in the last quarter, including HighTower Advisors LLC. Company insiders that have sold Tyme Technologies company stock in the last year include Michael Demurjian, and Steve Hoffman.
View insider buying and selling activity for Tyme Technologies or view top insider-selling stocks.

TYME stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Axiom Investment Management LLC, Northern Trust Corp, Barclays PLC, Meitav Dash Investments Ltd., Personal CFO Solutions LLC, and Quilter Plc. Company insiders that have bought Tyme Technologies stock in the last two years include Barbara Galaini, David Carberry, Douglas A Michels, James Biehl, Michele Ilene Korfin, Steve Hoffman, and Tornout Jan M Van.
View insider buying and selling activity for Tyme Technologies or or view top insider-buying stocks.

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TYME stock can currently be purchased for approximately $1.14.

Tyme Technologies has a market capitalization of $148.69 million. The company earns $-22,000,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

Tyme Technologies employs 18 workers across the globe.

The official website for Tyme Technologies is www.tymeinc.com.

Tyme Technologies is headquartered at 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004.

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]